Comparative manufacture and cell-based delivery of antiretroviral nanoformulations

International Journal of Nanomedicine

Volumn 6, Issue , 2011, Pages 3393-3404

  Balkundi, Shantanu ^a   Nowacek, Ari S ^a   Veerubhotla, Ram S ^a   Chen, Han ^b   Martinez Skinner, Andrea ^a   Roy, Upal ^a   Mosley, R Lee ^a,c   Kanmogne, Georgette ^a   Liu, Xinming ^a,c   Kabanov, Alexander V ^c   Bronich, Tatiana ^c   McMillan, Joellyn ^a   Gendelman, Howard E ^a,c  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA LINCOLN   (United States)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Human immunodeficiency virus type one; Manufacturing techniques; Monocyte derived macrophage; Nanoformulated antiretroviral therapy; Nanotoxicology

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ATAZANAVIR; BENZOXAZINE DERIVATIVE; EFAVIRENZ; INDINAVIR; NANOPARTICLE; OLIGOPEPTIDE; PYRIDINE DERIVATIVE; RITONAVIR;

ARTICLE; CELL SURVIVAL; CHEMISTRY; COMPARATIVE STUDY; CYTOCHEMISTRY; DRUG EFFECT; HUMAN; MACROPHAGE; METABOLISM; METHODOLOGY; NANOMEDICINE; NANOTECHNOLOGY; ULTRASOUND;

ANTI-HIV AGENTS; BENZOXAZINES; CELL SURVIVAL; CHEMISTRY, PHARMACEUTICAL; HISTOCYTOCHEMISTRY; HUMANS; INDINAVIR; MACROPHAGES; NANOMEDICINE; NANOPARTICLES; NANOTECHNOLOGY; OLIGOPEPTIDES; PYRIDINES; RITONAVIR; SONICATION;

EID: 84864762785     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S27830     Document Type: Article

References (39)

1. Delaugerre C, Peytavin G, Dominguez S, et al. Virological and pharmacological factors associated with virological response to salvage therapy after an 8-week of treatment interruption in a context of very advanced HIV disease (GigHAART ANRS 097). J Med Virol. 2005;77(3):345–350.
2. Duval X, Peytavin G, Albert I, et al. Determination of indinavir and nelf inavir trough plasma concentration eff icacy thresholds according to virological response in HIV-infected patients. HIV Med. 2004;5(4):307–313.
3. Hawkins T. Appearance-related side effects of HIV-1 treatment. AIDS Patient Care STDS. 2006;20(1):6–18.
4. Nowacek A, Gendelman HE. NanoART, neuroAIDS and CNS drug delivery. Nanomed. 2009;4(5):557–574.
5. Shehu-Xhilaga M, Tachedjian G, Crowe SM, Kedzierska K. Antiretroviral compounds: mechanisms underlying failure of HAART to eradicate HIV-1. Curr Med Chem. 2005;12(15):1705–1719.
6. Alos L, Navarrete P, Morente V, et al. Immunoarchitecture of lymphoid tissue in HIV-infection during antiretroviral therapy correlates with viral persistence. Mod Pathol. 2005;18(1):127–136.
7. Best BM, Letendre SL, Brigid E, et al. Low atazanavir concentrations in cerebrospinal fluid. Aids. 2009;23(1):83–87.
8. Murri R, Lepri AC, Cicconi P, et al. Is moderate HIV viremia associated with a higher risk of clinical progression in HIV-infected people treated with highly active antiretroviral therapy: evidence from the Italian cohort of antiretroviral-naive patients study. J Acquir Immune Defic Syndr. 2006;41(1):23–30.
9. Pathan SA, Iqbal Z, Zaidi SM, et al. CNS drug delivery systems: novel approaches. Recent Pat Drug Deliv Formul. 2009;3(1):71–89.
10. Varatharajan L, Thomas SA. The transport of anti-HIV drugs acr oss bl ood-CNS i nt er f aces: summar y of cur r ent knowl-edge and recommendations for further research. Antiviral Res. 2009;82(2):A99–A109.
11. Nowacek AS, Balkundi S, McMillan J, et al. Analyses of nanoformulated antiretroviral drug charge, size, shape and content for uptake, drug release and antiviral activities in human monocyte-derived macrophages. J Control Release. 2011;150(2):204–211.
12. Nowacek AS, McMillan J, Miller R, Anderson A, Rabinow B, Gendelman HE. Nanoformulated antiretroviral drug combinations extend drug release and antiretroviral responses in HIV-1-infected macrophages: implications for neuroAIDS therapeutics. J Neuroimmune Pharmacol. 2010;5(4):592–601.
13. Dou H, Destache CJ, Morehead JR, et al. Development of a macrophage-based nanoparticle platform for antiretroviral drug delivery. Blood. 2006;108(8):2827–2835.
14. Dou H, Grotepas CB, McMillan JM, et al. Macrophage delivery of nanoformulated antiretroviral drug to the brain in a murine model of neuroAIDS. J Immunol. 2009;183(1):661–669.
15. Nowacek AS, Miller RL, McMillan J, et al. NanoART synthesis, charact eri zat i on, upt ake, rel ease and t oxi col ogy for human monocyte-macrophage dr ug deliver y. Nanomedicine (Lond). 2009;4(8):903–917.
16. Balkundi S, Nowacek AS, Roy U, Martinez-Skinner A, McMillan J, Gendelman HE. Methods development for blood borne macrophage carriage of nanoformulated antiretroviral drugs. J Vis Exp. 2010;46. pii: 2460. doi: 10.3791/2460.
17. Bressani RF, Nowacek AS, Singh S, et al. Pharmacotoxicology of monocyte-macrophage nanoformulated antiretroviral drug uptake and carriage. Nanotoxicology. 2010;5:592–605.
18. Corrias F, Lai F. New methods for lipid nanoparticles preparation. Recent Pat Drug Deliv Formul. 2011;5(3):201–213.
19. Destache CJ, Belgum T, Goede M, Shibata A, Belshan MA. Antiretroviral release from poly(DL-lactide-co-glycolide) nanoparticles in mice. J Antimicrob Chemother. 2010;65(10):2183–2187.
20. Dou H, Morehead J, Destache CJ, et al. Laboratory investigations for the morphologic, pharmacokinetic, and anti-retroviral properties of indinavir nanoparticles in human monocyte-derived macrophages. Virology. 2007;358(1):148–158.
21. Mainardes RM, Evangelista RC. PLGA nanoparticles containing praziquantel: effect of formulation variables on size distribution. Int J Pharm. 2005;290(1–2):137–144.
22. Rabinow BE. Nanosuspensions in drug delivery. Nat Rev Drug Discov. 2004;3(9):785–796.
23. Shegokar R, Jansch M, Singh KK, Muller RH. In vitro protein adsorption studies on nevirapine nanosuspensions for HIV/AIDS chemotherapy. Nanomedicine. 2011;7(3):333–340.
24. Takatsuka T, Endo T, Jianguo Y, Yuminoki K, Hashimoto N. Nanosizing of poorly water soluble compounds using rotation/revolution mixer. Chem Pharm Bull (Tokyo). 2009;57(10):1061–1067.
25. Nakarani M, Patel P, Patel J, Murthy RS, Vaghani SS. Cyclosporine a-nanosuspension: formulation, characterization and in vivo comparison with a marketed formulation. Sci Pharm. 2010;78(2):345–361.
26. Niwa T, Miura S, Danjo K. Universal wet-milling technique to prepare oral nanosuspension focused on discovery and preclinical animal studies – Development of particle design method. Int J Pharm. 2011;405(1–2):218–227.
27. Dest ache CJ, Bel gum T, Chri st ensen K, et al. Combi nat i on antiretroviral drugs in PLGA nanoparticle for HIV-1. BMC Infect Dis. 2009;9:198.
28. Reddy MK, Wu L, Kou W, Ghorpade A, Labhasetwar V. Superoxide dismutase-loaded PLGA nanoparticles protect cultured human neurons under oxi dat ive st ress. Appl Bi ochem Bi ot echnol. 2008;151(2–3):565–577.
29. Gendel man HE, Orenst ei n JM, Mar t i n MA, et al. Eff i ci ent isolation and propagation of human immunodef iciency virus on recombinant colony-stimulating factor 1-treated monocytes. J Exp Med. 1988;167(4):1428–1441.
30. Kalter DC, Nakamura M, Turpin JA, et al. Enhanced HIV replication in macrophage colony-stimulating factor-treated monocytes. J Immunol. 1991;146(1):298–306.
31. Swindells S, DiRienzo AG, Wilkin T, et al. Regimen simplif ication to atazanavir-ritonavir alone as maintenance antiretroviral therapy aft er sust ai ned vi rol ogi c suppressi on. JAMA. 2006; 296(7): 806–814.
32. Swindells S, Flexner C, Fletcher CV, Jacobson JM. The critical need for alternative antiretroviral formulations, and obstacles to their development. J Infect Dis. 2011;204(5):669–674.
33. Deeks ED, Perry CM. Efavirenz/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen (Atripla(R)): a review of its use in the management of HIV infection. Drugs. 2010;70(17):2315–2338.
34. Kadiu I, Nowacek A, cMillan J, Gendelman HE. Macrophage endocytic trafficking of antiretroviral nanoparticles. Nanomedicine. 2011;6(1):25–42.
35. Johnson M, Grinsztejn B, Rodriguez C, et al. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. Aids. 2005;19(7):685–694.
36. Martins S, Ramos MJ, Fernandes PA. The current status of the NNRTI family of antiretrovirals used in the HAART regime against HIV infection. Curr Med Chem. 2008;15(11):1083–1095.
37. Haas DW, Ribaudo HJ, Kim RB, et al. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. Aids. 2004;18(18):2391–2400.
38. Murray JL, Mavrakis M, McDonald NJ, et al. Rab9 GTPase is required for replication of human immunodeficiency virus type 1, filoviruses, and measles virus. J Virol. 2005;79(18):11742–11751.
39. Varthakavi V, Smith RM, Martin KL, et al. The pericentriolar recycling endosome plays a key role in Vpu-mediated enhancement of HIV-1 particle release. Traffic. 2006;7(3):298–307.